Skip to main content

Advertisement

SpringerLink
Log in

Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

There is no agreement on which channel is involved in oxaliplatin neurotoxicity, most investigators favouring voltage-gated sodium channels. However, the small conductance Ca++ activated K+ channels, encoded by the SK1–3 genes, are also involved in membrane excitability, playing a role in after-hyperpolarization at the motor nerve terminal. As the SK3 gene is characterized in Caucasians by a highly polymorphic CAG motif within the exon 1, we hypothesize that SK3 gene polymorphism may influence the development of acute nerve hyperexcitability in oxaliplatin-treated patients.

Methods

Patients eligible for an oxaliplatin-containing regimen were enrolled. Detailed neurological examination, nerve conduction studies and needle electromyography were performed before and after oxaliplatin administration. DNA was extracted by polymerase chain reaction, and each allele was isolated and sequenced.

Results

We evaluated 40 patients. After oxaliplatin administration, 28 patients developed symptoms of neurotoxicity, which were severe in 11. Patients were divided into three groups according to neurophysiological data: G0 (normal peripheral nerve excitability [PNE]), 16 patients; G1 (mild PNE), 15 patients; G2 (severe PNE), 9 patients. Genetic analysis showed different alleles ranging from 13 to 23 CAG repeats. Patients carrying alleles containing 13–15 CAG repeats experienced a significantly higher incidence of severe nerve hyperexcitability (chi-square 48.6; df 16; P = 0.0001).

Conclusion

The results suggest that OXA-neurotoxicity may be related to distribution of the polymorphic CAG motif of the SK3 gene, which might modulate nerve after-hyperpolarization. The 13–14 CAG repeat allele could mark patients susceptible to acute OXA neurotoxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895–924

    Article  PubMed  CAS  Google Scholar 

  2. de Gramont A, Figer A, Seymour H, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  4. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29:21–33

    Article  PubMed  CAS  Google Scholar 

  5. Cassidy J, Misset JL (2002) Oxaliplatin-related side-effects: characteristics and management. Semin Oncol 29:11–20

    Article  PubMed  CAS  Google Scholar 

  6. Screnci D, McKeage M (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77:105–110

    Article  PubMed  CAS  Google Scholar 

  7. Wilson RH, Lehky T, Rebecca RT, Quinn MG, Floeter MK, Grem JL (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767–1774

    Article  PubMed  CAS  Google Scholar 

  8. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387–392

    Article  PubMed  CAS  Google Scholar 

  9. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR (2002) Phenotypic variants of autoimmune perypheral nerve hyperexcitability. Brain 125:1887–1895

    Article  PubMed  Google Scholar 

  10. Hart IK, Waters C, Vincent A, Newland C, Beeson D, Pongs O, Morris C, Newsom-Davis J (1997) Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann Neurol 41:238–246

    Article  PubMed  CAS  Google Scholar 

  11. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C (2000) The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25–32

    Article  PubMed  CAS  Google Scholar 

  12. Webster RG, Brain KL, Wilson RH, Grem JL, Vincent A (2005) Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. British J Pharmacol 146:1027–1039

    Article  CAS  Google Scholar 

  13. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Phelate M, Gamelin E (2001) A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293–2297

    PubMed  CAS  Google Scholar 

  14. Basso M, Cassano A, Modoni A, Spada D, Trigila N, Quirino M, Schinzari G, Barone C (2008) A reversibile coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance. Eur J Clin Pharmacol 64:739–741

    Article  PubMed  Google Scholar 

  15. Kimura T, Takahashi MP, Fujimura H, Sakoda S (2003) Expression and distribution of a small-conductance calcium-activated potassium channel (SK3) protein in skeletal muscles from myotonic muscular dystrophy patients and congenital myotonic mice. Neurosci Lett 347:191–195

    Article  PubMed  CAS  Google Scholar 

  16. Wittekindt O, Jauch A, Burgert E, Scharer L, Holtgreve-Grez H, Yvert G, Imbert G, Zimmer J, Hoehe MR, Macher JP, Chiaroni P, van Calker D, Crocq MA, Morris-Rosendahl DJ (1998) The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia. Neurogenetics 1:259–265

    Article  PubMed  CAS  Google Scholar 

  17. Chandy KG, Fantino E, Wittekindt O, Kalman K, Tong LL, Ho TH, Gutman GA, Crocq MA, Ganguli R, Nimgaonkar V, Morris-Rosedahl DJ, Gargus JJ (1998) Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate gene for schizophrenia and bipolar disorder. Mol Psychiatry 3:32–37

    Article  PubMed  CAS  Google Scholar 

  18. Frei E, Spindler I, Grissmer S, Jager H (2006) Interactions of N-terminal and C-terminal parts of the small conductance Ca2+ activated K+ channel, hSK3. Cell Physiol Biochem 18:165–176

    Article  PubMed  CAS  Google Scholar 

  19. Miller SA, Dykes DD, Plensky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215

    Article  PubMed  CAS  Google Scholar 

  20. Austin CP, Holder DJ, Ma L, Mixson LA, Caskey CT (1999) Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia. Mol Psychiatry 4:261–266

    Article  PubMed  CAS  Google Scholar 

  21. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 26:(abstract 4010)

  22. McIntyre CC, Richardson AG, Grill WM (2002) Modeling the excitability of mammalian nerve fibers: influence of afterpotentials on recovery cycle. J Neurophysiol 87:995–1006

    PubMed  Google Scholar 

  23. Wittekindt OH, Visan V, Tomita H, Imtiaz F, Gargus JJ, Lehmann-Horn F, Grissmer S, Morris-Rosendahl DJ (2004) An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel. Mol Pharmacol 65:788–801

    Article  PubMed  CAS  Google Scholar 

  24. Tomimitsu H, Kimiyoshi A, Nagado T, Watanabe O, Otsuka R, Kurono A, Sonoda Y, Osame M, Kameyama M (2004) Mechanism of action of voltage-gated K+ channels antibodies in acquired neuromyotonia. Ann Neurol 56:440–444

    Article  PubMed  CAS  Google Scholar 

  25. Mark Duffy S, Berger P, Cruse G, Yang W, Bolton SJ, Bradding P (2004) The K+ channels iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells. J Allergy Clin Immunol 114:66–72

    Article  PubMed  CAS  Google Scholar 

  26. Maindrault-Goebel F, Andrè T, Tournigand C, Louvet C, Perez-Staub N, Zaghib N, de Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patinets. Eur J Cancer 41:2262–2267. [Epub 2005 Sep 9]

    Google Scholar 

  27. Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259–261. [Epub 2005 Nov 9]

    Google Scholar 

Download references

Conflict of interest

Carlo Barone was a consultant for Amgen, Merck and Roche.

Author information

Authors and Affiliations

  1. Medical Oncology, Department of Internal Medicine, Catholic University of Sacred Heart, Largo Agostino Gemelli n. 8, 00168, Rome, Italy

    Michele Basso, Daniele Spada, Alessandra Cassano, Giovanni Schinzari & Carlo Barone

  2. Department of Neuroscience, Catholic University of Sacred Heart, Rome, Italy

    Anna Modoni, Mauro Lo Monaco, Davide Quaranta & Pietro Attilio Tonali

Authors
  1. Michele Basso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Modoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniele Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandra Cassano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Schinzari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mauro Lo Monaco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Davide Quaranta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pietro Attilio Tonali
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carlo Barone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Barone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basso, M., Modoni, A., Spada, D. et al. Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol 67, 1179–1187 (2011). https://doi.org/10.1007/s00280-010-1466-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-010-1466-y

Keywords

Search

Navigation